A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi
A phase 1/2 trial of Cevostamab, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05535244 by Hoffmann-La Roche, with 90 participants planned, started 2022-10-17 and due to reach its primary completion in 2027-02-26. Interventions recorded: Cevostamab, Tocilizumab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Cevostamab, Roche / Genentech, Multiple myeloma.
- TrialA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Shares Cevostamab, Tocilizumab, Roche / Genentech, Multiple myeloma.
- TrialA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Shares Tocilizumab, Roche / Genentech.
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Tocilizumab, Roche / Genentech.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti
Shares Tocilizumab, Roche / Genentech.
- TrialA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps
Shares Tocilizumab, Multiple myeloma.
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Tocilizumab, Roche / Genentech.
- TrialA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi
Shares Tocilizumab, Roche / Genentech.